Compare SYSCO Corporation (SYY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs TransMedics Group Inc — how do they compare? SYSCO Corporation trades at $78.58 (market cap $38.47B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: SYSCO Corporation is far larger — about 14× TransMedics Group Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and TransMedics Group Inc for 24 Days on average.
| SYY | TMDX | |
|---|---|---|
Market Cap | $38.47B | $2.74B |
Volume | 4,808,465 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $150.42 |
52-Week Low | $69.30 | $61.99 |
Typical Hold Time | 77 Days | 24 Days |
Enterprise Value | $51.65B | $3.13B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $78.14, up 1.76% with neutral technical signals. The company maintains steady revenue growth reaching $81.37B in 2025, though net margins compressed to 2.08%. Recent corporate actions include a $1.5B senior notes offering and a $0.55 dividend declaration. Technical indicators show mixed signals with RSI neutral at 49.4 and ADX suggesting weak trend direction. The stock trades below analyst consensus target of $85.75 with 60% buy ratings.
Sysco presents a balanced investment case with attractive valuation metrics (P/S 0.44) and strong institutional support, offset by margin pressure and elevated debt levels. The AI efficiency program targeting $500M savings by 2029 provides growth catalyst potential. Key risks include competitive pressures in food distribution and sensitivity to economic cycles affecting restaurant demand.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
